Future directions for checkpoint inhibitors in cutaneous lymphoma treatment

Future directions for checkpoint inhibitors in cutaneous lymphoma treatment

VJHemOnc

1 year
100 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Michael Khodadoust, MD, PhD, of the Stanford University School of Medicine, Stanford, CA, discusses the future of checkpoint inhibitors in cutaneous lymphoma. He highlights the follow-up trial to CITN-10, CITN-13, which investigated pembrolizumab plus interferon-gamma 1b in relapsed/ refractory mycosis fungoides or Sézary syndrome (NCT03063632). He calls for the development of predictive markers of pembrolizumab response for cutaneous lymphoma, as well as research into synergist agents to improve response rates. This video was recorded at the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland
Up Next Autoplay
Accelerating clinical trials in transplantation
Accelerating clinical trials in transplantation
Category: Acute Myelogenous Leukemia
1,218 Views
VJHemOnc 1 year
Whole genome sequencing opens door for targeted Waldenström’s therapy
Whole genome sequencing opens door for targeted Waldenström’s therapy
Category: Multiple Myeloma
821 Views
VJHemOnc 1 year
Updated POLLUX results for early relapsed myeloma patients
Updated POLLUX results for early relapsed myeloma patients
Category: Multiple Myeloma
935 Views
VJHemOnc 1 year
Targeting BCMA with bispecific antibodies in R/R myeloma
Targeting BCMA with bispecific antibodies in R/R myeloma
Category: Multiple Myeloma
969 Views
VJHemOnc 1 year
Monoclonal antibodies: current and future potential
Monoclonal antibodies: current and future potential
Category: General
767 Views
VJHemOnc 1 year
Plasma cell leukemia and extramedullary disease in multiple myeloma
Plasma cell leukemia and extramedullary disease in multiple myeloma
Category: General
275 Views
VJHemOnc 1 year
Judging the value of a clinical trial in hem-onc
Judging the value of a clinical trial in hem-onc
Category: General
54 Views
VJHemOnc 1 year
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
Updated CASTOR analysis: daratumumab plus Vd for R/R myeloma
Category: Multiple Myeloma
100 Views
VJHemOnc 1 year
Future treatment combinations for myeloma
Future treatment combinations for myeloma
Category: Melanoma and Skin Cancer
124 Views
VJHemOnc 1 year
Continuous vs. fixed duration therapy for multiple myeloma?
Continuous vs. fixed duration therapy for multiple myeloma?
Category: Multiple Myeloma
60 Views
VJHemOnc 1 year